FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

Nov 13 (Reuters) - Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.

The drug, empagliflozin, was approved in 2014 in doses of 10 mg and 20 mg to help lower blood sugar levels in patients with type 2 diabetes and is marketed as Jardiance.

Boehringer Ingelheim has proposed a 2.5 mg dose of empagliflozin for use in type 1 diabetes to help lower the risk of diabetic ketoacidosis, an inherent complication associated with the condition.

The FDA is yet to take a decision on empagliflozin's use in type 1 diabetes. While the agency is not bound to follow the recommendation of its advisory panels, it usually does so. (Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Sriraj Kalluvila and Shounak Dasgupta)